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The COVID-19 pandemic has resulted in the development 
of highly effective vaccines that provide hope to the 
global community for reducing the spread of SARS-CoV-2 
and limiting the mortality and morbidity caused by the 
disease. These vaccines have been produced using differing 
technologies, taken through clinical trials, and rolled out 
across the UK at unprecedented speed. However, the recent 
emergence of rare cases of life-threatening thrombosis in 
association with thrombocytopenia has threatened to derail 
one particular vaccine, the Oxford AstraZeneca ChAdOx1 
vaccine, upon which many countries are dependent for their 
vaccination programmes. The story of how this situation has 
been managed in the UK at the height of the vaccine roll-out 
represents a remarkable collective endeavour on the part of 
the haematology community, working closely with other acute 
medical and surgical professionals within the NHS and the UK 
health regulatory bodies, to provide rapid expert guidance 
that has saved lives and helped keep the national vaccination 
programme on track.
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The COVID-19 pandemic has resulted in the development 
of highly effective vaccines that provide hope to the global 
community for reducing the spread of SARS-CoV-2 and limiting 
the mortality and morbidity caused by the disease. These vaccines 
have been produced using differing technologies, taken through 
clinical trials, and rolled out across the UK at unprecedented 
speed. However, the recent emergence of rare cases of life-
threatening thrombosis in association with thrombocytopenia 
has threatened to derail one particular vaccine, the Oxford 
AstraZeneca ChAdOx1 vaccine, upon which many countries are 
dependent for their vaccination programmes.1 The story of how 
this situation has been managed in the UK at the height of the 
vaccine roll-out represents a remarkable collective endeavour on 
the part of the haematology community, working closely with 
other acute medical and surgical professionals within the NHS, 
and the UK health regulatory bodies, to provide rapid expert 
guidance that has saved lives and helped keep the national 
vaccination programme on track.
Vaccine-induced immune thrombocytopenia and thrombosis 
(VITT) is a rare syndrome affecting around one person in 
50,000–100,000 people vaccinated with ChAdOx1. Patients 
present with serious symptoms 5–30 days post-vaccination, 
except in some cases with isolated deep vein thrombosis and 
pulmonary embolism, where presentation is up to 42 days post-
vaccination. Patients frequently exhibit very high D-dimer levels, 
often with low fibrinogen, but the key defining laboratory test is 
the demonstration of antibodies to platelet factor 4 (PF4). These 
antibodies, recognised as being similar to those seen in heparin-
induced thrombocytopenia (HIT), are detected by ELISA-based 
HIT assays (Lifecodes, Asserachrom and Zymutest); interestingly, 
they are often not detected by non-ELISA HIT assays, suggesting 
immunological differences exist between the two conditions.2 
These anti-PF4 antibodies cause platelet activation leading 
to thrombocytopenia and acute thrombosis, often in unusual 
sites. Cerebral venous sinus thrombosis (CVST) accounts for 
approximately 50% of presentations and tends to be much more 
extensive than non-VITT CVST, leading to cerebral oedema, raised 
intracranial pressure, and secondary intracranial haemorrhage 
with high mortality, especially if associated with severe 
thrombocytopenia. Other sites include portal and splanchnic 
veins, deep vein thrombosis and pulmonary embolism, and arterial 
ischaemia.
VITT was first described by groups in Norway and Germany 
among recipients of the ChAdOx1 vaccine in those countries, 
leading to temporary cessation of the vaccine within the European 
Union.3,4 This was soon followed by a larger series from the UK 
that defined clinical aspects of VITT and its laboratory diagnosis.5 
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Interestingly, VITT-like cases have also been reported in patients 
who have received the Janssen COVID-19 vaccine (Ad26.COV2.S), 
causing its temporary cessation in the USA and potentially 
implicating the adenoviral vector in these vaccines. However, more 
recently, cases of possible VITT have been reported following the 
Pfizer BioNTech (BNT162b2) and Moderna (mRNA-1273) vaccines, 
suggesting the syndrome may be a very rare side-effect of the 
mRNA COVID-19 vaccines also.
The emergence of VITT as a rare but serious adverse event 
complicating COVID-19 vaccination prompted urgent action from 
the haematology community resulting in the rapid formation of 
an Expert Haematology Panel (EHP) to advise on the investigation 
and management of suspected cases. Most importantly, the panel 
has produced living guidance that is hosted on the British Society 
for Haematology website.6 It is based on available evidence and 
expert opinion in a rapidly evolving situation. The panel has met 
online almost daily since it was originally convened on 22 March 
2021 when cases first started emerging and, to date, has advised 
on over 300 potential VITT cases, the clinical features of which 
have recently been published.7 Since then, the activities of the EHP 
have proven far-reaching in providing guidance internationally 
for managing patients with VITT, and in raising awareness of the 
syndrome among multidisciplinary primary and secondary care 
health professionals. Members of the panel have also conducted 
multi-media interviews with careful balance so as not to jeopardise 
public confidence in the essential vaccination programme, as 
has been seen in other countries. However, while VITT remains 
extremely rare, the diagnosis is potentially catastrophic for affected 
individuals, often young and healthy, who may have chosen to 
receive a vaccine for public rather than personal health reasons.
The way the haematology community came together to deal 
with the emerging VITT ‘crisis’ is a story that is emblematic of 
the many remarkable personal efforts made by NHS healthcare 
professionals throughout the COVID-19 pandemic. Here, we have 
outlined some of the main achievements of the EHP since its 
inception.
 > To provide mutual and expert opinion to haematologists and 
other relevant healthcare professionals (including intensivists, 
neurologists, neurosurgeons, cardiologists, radiologists and 
pathologists), who have been able to share cases daily via 
online panel meetings with support provided at other times via 
phone and email. The rapid dissemination of an awareness of 
VITT syndrome among haematologists, and best practice for 
treating affected individuals, was deemed critical for providing 
local expertise for acute NHS trusts where patients were 
presenting, often with atypical symptoms.
 > To generate live and accessible guidelines highlighting the 
importance of local haematology support to advise on best 
treatment based on urgent administration of intravenous 
immunoglobulin, non-heparin anticoagulation (typically 
argatroban infusion or fondaparinux) and, in severe cases, 
transfer to specialist centres for plasma exchange or for 
neurosurgical intervention. Most VITT patients also received 
steroid immunosuppression (usually dexamethasone), while 
rituximab has been used for more refractory cases or those who 
have relapsed.
 > To raise awareness of the VITT syndrome with relevant 
authorities within the UK, facilitating informed policy decision 
making, and to work with them as understanding of the 
condition increased. This has included the chief medical officer 
(CMO), Joint Committee for Vaccination and Immunisation 
(JCVI), Medicine and Healthcare Regulatory Authority (MHRA), 
Public Health England (PHE), NHS England (NHSE) and the 
Department of Health. Indeed, the evidence provided by the 
EHP to these bodies was arguably central to the joint decision 
by the JCVI and the MHRA to offer the Pfizer vaccine exclusively 
to individuals below 30 years of age, and subsequently 
extended to those up to 40 years, where the risk:benefit ratio of 
vaccination was considered marginal given dwindling numbers 
of COVID-19 cases across the UK at that time. Confidence 
in the vaccination programme was deemed critical among 
these age groups, to whom successful continued roll-out of 
the vaccination programme is proving central to impeding the 
spread of the highly transmissible Delta variant of SARS-CoV-2.
 > To help shape the public message regarding the very small 
but real risk of vaccination attributable to VITT that the 
government and CMO have disseminated to the public via 
PHE, the MHRA and the JCVI. This distribution of relevant 
information also included key haematologists within the 
devolved nations of the UK who could liaise effectively with 
their respective health authorities.
 > To provide timely advice and practical guidance to general 
practitioners, via the Royal College of General Practitioners, 
to help address genuine public worry among recipients of the 
AstraZeneca vaccine who had experienced severe headaches 
or other symptoms of concern post-vaccination. Balancing the 
perception of risk from vaccination against the very real risk 
of death from COVID-19 if unvaccinated against an ongoing 
challenge in the UK and globally.
 > To produce guidelines in collaboration with the Royal College 
of Emergency Medicine for dealing with worried patients 
presenting to emergency departments. The VITT situation 
clearly presented a risk of over-burdening hospital services 
and radiological scanner capacity. Red flag markers were 
identified including severity of unexplained symptoms, the 
timeframe of their onset post-vaccination and the presence of 
thrombocytopenia on full blood count testing. The guidelines 
highlighted rapid involvement of a local haematologist for 
assessing likelihood of diagnosis based on measurement 
of D-dimers, fibrinogen and urgent PF4 antibody testing by 
specialist laboratories.
 > To collaborate with the neurological community to produce 
multidisciplinary guidelines on optimal neurological 
management of CVST (involving neurologists, neurosurgeons, 
neuroradiologists and intensivists who often have different 
approaches for dealing with these critically ill patients). The 
focus here was directed primarily at immediate intervention 
with intravenous immunoglobulins to block platelet activation 
combined with therapeutic anticoagulation to limit thrombus 
propagation.
 > To identify a particularly poor prognostic group and 
recommend escalation of treatment to early plasma exchange 
for those patients with clinical deterioration and severe 
thrombocytopenia who have an extremely high risk of mortality 
from intracranial haemorrhage and cerebral oedema. Decisions 
regarding surgical decompression and/or thrombectomy, as 
well as when to administer platelets and plasma products pre-
operatively, require rapid multidisciplinary discussions.
 > To collaborate with NHS Blood and Transplant to help generate 
guidelines relevant to the donation of organs from deceased 
VITT patients whose organs might be non-viable due to small 
© Royal College of Physicians 2021. All rights reserved. 3
VITT, COVID-19 and the EHP
vessel thromboses and whose blood might carry the potential 
for inducing iatrogenic VITT in the recipient.
 > To develop written patient information for individuals 
diagnosed with VITT, including avoidance of repeat vaccination 
with the AstraZeneca vaccine, and to provide appropriate 
recommendations to physicians regarding follow-up management 
and optimal anti-coagulation and/or anti-platelet therapy.
 > To engage the help of NHSE in monitoring the national 
shortage of intravenous immunoglobulin and to ensure that 
supplies were safeguarded and prioritised to be immediately 
available at all UK hospitals for any VITT patients who required 
them.
 > To develop National Institute for Health and Care Excellence 
guidelines that would serve as an international reference for 
doctors elsewhere in the world, particularly resource-poor 
countries who are heavily reliant on the Oxford AstraZeneca 
vaccine.8
 > To establish a national commitment for psychological and 
social support for patients and their families involving the CMO, 
NHSE and PHE, as well as working closely with Thrombosis UK 
who have been providing support to individuals with VITT, their 
families and the bereaved.
 > To collaborate with the MHRA and facilitate and conduct 
relevant scientific studies focused on understanding the 
pathogenic mechanism of VITT that will be required for 
improved treatment and even prevention of this disease in 
the future, including vaccine design and identification of risk 
factors. These studies have included whole genome sequencing, 
immunological analysis, platelet activation assays and in vitro 
drug testing, and have already identified novel strategies for 
switching off platelet activation resulting in candidate therapies 
to be tested in future international trials.
In summary, with the emergence of a new life-threatening 
condition, the haematology community have risen to the 
challenge to define it, explore best treatments and engage with 
all areas within clinical care to ensure that if a patient is diagnosed 
with VITT anywhere in the UK, they will receive up-to-date 
consensus management and follow-up. This has required many 
hours of altruistic input, and we salute all those involved who have 
given their time freely. ■
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